Drugs for Cryopyrin-Associated Periodic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 72)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Plasminogen |
Approved |
Phase 4 |
|
9001-91-6 |
|
Synonyms:
1-glutamylplasminogen
Human plasminogen
Plasma trypsinogen
|
plasminogen, human-tvmh
Profibrinolysin
|
|
2 |
|
Ambrisentan |
Approved, Investigational |
Phase 4 |
|
177036-94-1 |
6918493 |
Synonyms:
(2S)-2-[(4,6-DIMETHYLPYRIMIDIN-2-YL)OXY]-3-METHOXY- 3,3-DIPHENYLPROPANOIC ACID
AMBRISENTAN
GSK1325760
GSK-1325760
GSK1325760A
|
GSK-1325760A
LETAIRIS
Letairis®
LU-208075
VOLIBRIS
|
|
3 |
|
Spironolactone |
Approved |
Phase 4 |
|
1952-01-7, 52-01-7 |
5833 |
Synonyms:
ABBOLACTONE
Acelat
Aldace
Aldactazide
Aldactide
Aldactone
Aldactone a
Aldactone®|spiractin|spirotone
Alderon
Aldopur
Almatol
Alphapharm brand OF spironolactone
Alpharma brand OF spironolactone
Alter brand OF spironolactone
Altex
Aquareduct
Ashbourne brand OF spironolactone
Azupharma brand OF spironolactone
Betapharm brand OF spironolactone
Cardel brand OF spironolactone
CAROSPIR
CT Arzneimittel brand OF spironolactone
CT, Spiro von
CT-Arzneimittel brand OF spironolactone
Deverol
Dexo brand OF spironolactone
DIATENSEC
Dira
Duraspiron
Espironolactona
Espironolactona [INN-Spanish]
Espironolactona alter
Espironolactona mundogen
Euteberol
Flumach
Frumikal
Generosan brand OF spironolactone
GX SPIRONOL
Hormosan brand OF spironolactone
Jenapharm brand OF spironolactone
Jenaspiron
Lacalmin
Lacdene
LARACTONE
Mayoly-spindler brand OF spironolactone
Melarcon
Merck dura brand OF spironolactone
Mundogen brand OF spironolactone
Nefurofan
Novo spiroton
Novopharm brand OF spironolactone
Novo-spiroton
NovoSpiroton
NSC-150399
Osyrol
Pfizer brand OF spironolactone
|
Pharmafrid brand OF spironolactone
Practon
Roche brand OF spironolactone
Sagisal
SC-9420
Searle brand OF spironolactone
Sincomen
SNL
Spiractin
Spiresis
SPIRETIC
Spiridon
SPIRNOLACTONE
Spiro l.u.t.
Spiro von CT
Spirobeta
Spiroctan
SPIROCTAN 100
SPIROCTAN 25
SPIROCTAN 50
Spiroctanie
Spiroderm
Spirogamma
Spirolactone
Spirolakton
Spirolang
Spirolone
Spirone
Spirono isis
Spironocompren
Spirono-isis
SPIRONOLACTONE
Spironolactone [BAN:INN:JAN]
Spironolactone A
Spironolactonum
Spironolactonum [INN-Latin]
Spironolattone
Spironolattone [DCIT]
Spironone
Spirospare
SPIROSPARE 100
SPIROSPARE 25
Spiro-Tablinen
SPIROTONE
Sprioderm
Supra-puren
Suracton
Uractone
Urusonin
Veroshpiron
Verospiron
Verospirone
Verospirone Opianin
Von CT, spiro
Wörwag brand OF spironolactone
Xenalon
|
|
4 |
|
Fibrinolytic Agents |
|
Phase 4 |
|
|
|
5 |
|
Tissue Plasminogen Activator |
|
Phase 4 |
|
|
|
6 |
|
Hormones |
|
Phase 4 |
|
|
|
7 |
|
Liver Extracts |
|
Phase 4 |
|
|
|
8 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
9 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
10 |
|
Diuretics, Potassium Sparing |
|
Phase 4 |
|
|
|
11 |
|
diuretics |
|
Phase 4 |
|
|
|
12 |
|
Natriuretic Peptide, Brain |
|
Phase 4 |
|
|
|
13 |
|
Mineralocorticoids |
|
Phase 4 |
|
|
|
14 |
|
Mineralocorticoid Receptor Antagonists |
|
Phase 4 |
|
|
|
15 |
|
Ginseng |
Investigational, Nutraceutical |
Phase 4 |
|
50647-08-0 |
|
Synonyms:
4,8a-Bis[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] 2,3-dihydroxy-6b-(hydroxymethyl)-4,6a,11,11,14b-pentamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicene-4,8a-dicarboxylic acid
Aralia ginseng root
Asian ginseng root
Chinese ginseng root
GINSENG
Ginseng (panax ginseng)
Ginseng extract
Ginseng, asian
Hong shen root
Insam root
Korean ginseng
Korean ginseng root
Ninjin root
|
Panax ginseng
Panax ginseng root
Panax ginseng root extract
Panax schinseng root
Panax verus root
Prosapogenin
Prosapogenin a
Prosapogenin d'1
Red ginseng
Ren seng root
Ren shen
Ren shen root
True ginseng root
|
|
16 |
|
Rilonacept |
Approved, Investigational |
Phase 3 |
|
501081-76-1 |
|
Synonyms:
ARCALYST
IL-1 TRAP
IL-1-TRAP
|
interleukin-1 (IL-1) trap
INTERLEUKIN-1 TRAP
Rilonacept
|
|
17 |
|
Calcium polycarbophil |
Approved |
Phase 2, Phase 3 |
|
126040-58-2 |
|
Synonyms:
Calcium polycarbophil
Polycarbophil calcium
|
|
|
18 |
|
Cinnamon |
Approved |
Phase 2, Phase 3 |
|
|
|
19 |
|
Propofol |
Approved, Investigational, Vet_approved |
Phase 3 |
|
2078-54-8 |
4943 |
Synonyms:
2,6 Diisopropylphenol
2,6-Bis(1-methylethyl)phenol
2,6-Diisopropylphenol
2,6-diisopropylphenol|Diprivan®|ICI 35868
Abbott brand OF propofol
Alpha Brand OF propofol
Aquafol
Astra brand OF propofol
AstraZeneca brand OF propofol
Braun brand OF propofol
Curamed brand OF propofol
Diisopropylphenol
Diprivan
Disoprivan
Disoprofol
Fresenius brand OF propofol
Fresenius kabi brand OF propofol
Fresofol
ICI 35868
ICI 35-868
|
ICI35,868
ICI-35868
Ivofol
Juste brand OF propofol
NSC-5105
Parnell brand OF propofol
Pisa brand OF propofol
Propofol
Propofol abbott
Propofol fresenius
Propofol MCT
Propofol rovi
Propofol-lipuro
Propofolum
Rapinovet
Recofol
Rovi brand OF propofol
Schering brand OF propofol
Zeneca brand OF propofol
|
|
20 |
|
Analgesics |
|
Phase 3 |
|
|
|
21 |
|
Anti-Inflammatory Agents |
|
Phase 3 |
|
|
|
22 |
|
Antibodies, Monoclonal |
|
Phase 3 |
|
|
|
23 |
|
Psyllium |
|
Phase 2, Phase 3 |
|
|
|
24 |
|
Juzentaihoto |
|
Phase 2, Phase 3 |
|
|
|
25 |
|
Mitogens |
|
Phase 2, Phase 3 |
|
|
|
26 |
|
Analgesics, Opioid |
|
Phase 3 |
|
|
|
27 |
|
Narcotics |
|
Phase 3 |
|
|
|
28 |
|
Immunoglobulins |
|
Phase 3 |
|
|
|
29 |
|
Antibodies |
|
Phase 3 |
|
|
|
30 |
|
Docetaxel |
Approved, Investigational |
Phase 2 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
31 |
|
Flecainide |
Approved, Withdrawn |
Phase 2 |
|
54143-55-4 |
3356 |
Synonyms:
(+-)-Flecainide
(±)-flecainide
3m Brand OF flecainide acetate
Acetate, flecainide
Alphapharm brand OF flecainide acetate
Alpharma brand OF flecainide acetate
Apocard
CCRIS 313
Flecadura
Flecaine
Flecainid isis
Flecainida
Flecainida [INN-Spanish]
FLECAINIDE
Flécaïnide
Flecainide acetate
Flecainide monoacetate
Flecainide monoacetate, (+-)-isomer
|
Flecainide monoacetate, (R)-isomer
Flecainide monoacetate, (S)-isomer
Flecainide, (R)-isomer
Flecainide, (S)-isomer
Flecainide, 5-HO-N-(6-oxo)-derivative
Flecainide, 5-HO-N-(6-oxo)-derivative, (+-)-isomer
Flecainid-isis
Flecainidum
Flecainidum [INN-Latin]
Flecatab
Merck dura brand OF flecainide acetate
N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide
Riker brand OF flecainide acetate
Tambocor
Tambocor®
THN-102 COMPONENT FLECAINIDE
United drug brand OF flecainide acetate
|
|
32 |
|
Imipramine |
Approved |
Phase 2 |
|
50-49-7 |
3696 |
Synonyms:
10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,F]azepine-5-propanamine
3-(5H-DIBENZO[b,F]azepin-5-yl)-N,N-dimethylpropan-1-amine
4,4'-Methylenebis(3-hydroxy-2-naphthoic acid)-3-(10,11-dihydro-5H-dibenzo(b,F)azepin-5-yl)-N,N-dimethyl-1-propanamine (1:2)
5-[3-(Dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,F]azepine
Antideprin
Berkomine
Censtim
Censtin
Chimoreptin
Declomipramine
Dimipressin
DPID
Dynaprin
Dyna-zina
Estraldine
Eupramin
Feinalmin
IM
Imavate
Imidobenzyle
imidobenzyle|Tofranil®
Imilanyle
Imipramin
Imipramina
Imipramine
Imipramine Hcl
Imipramine hydrochloride
Imipramine monohydrochloride
Imipramine pamoate
Imipraminum
Imiprin
Imizin
Imizine
Imizinum
Impramine
|
Intalpram
Iramil
Irmin
Janimine
Lofepramine
Melipramin
Melipramine
N-(gamma-Dimethylaminopropyl)iminodibenzyl
N-(g-Dimethylaminopropyl)iminodibenzyl
N-(Γ-dimethylaminopropyl)iminodibenzyl
Nelipramin
Norchlorimipramine
Norfranil
NSC-169866
ORG-2463
PRAMINE
Prazepine
PRESAMINE
Promiben
Pryleugan
Psychoforin
Sk-Pramine
Surmontil
Surplix
Teperine
Timolet
Tipramine
Tofranil
Tofranil base
Tofranil, Base
Tofraniln A
Tofranil-PM
Tofranil-PM (imipramine pamoate)
Trimipramine maleate
|
|
33 |
|
Moricizine |
Approved, Investigational, Withdrawn |
Phase 2 |
|
31883-05-3 |
34633 |
Synonyms:
[10-(3-Morpholin-4-yl-propionyl)-10H-phenothiazin-2-yl]-carbamate ethyl ester
[10-(3-Morpholin-4-yl-propionyl)-10H-phenothiazin-2-yl]-carbamic acid ethyl ester
EN-313
EN-313 FREE BASE
Ethmozin
Ethmozine
Ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate
Ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamic acid
Ethyl 10-(beta-N-morpholinylpropionyl)phenothiazine-2-carbamate
Ethyl 10-(beta-N-morpholinylpropionyl)phenothiazine-2-carbamic acid
Ethyl 10-(b-N-morpholinylpropionyl)phenothiazine-2-carbamate
|
Ethyl 10-(b-N-morpholinylpropionyl)phenothiazine-2-carbamic acid
Ethyl 10-(β-N-morpholinylpropionyl)phenothiazine-2-carbamate
Ethyl 10-(β-N-morpholinylpropionyl)phenothiazine-2-carbamic acid
Etmozin
Hydrochloride, moricizine
Moracizin
Moracizina
Moracizine
Moracizinum
Moricizine
Moricizine hydrochloride
|
|
34 |
|
Encainide |
Approved, Investigational, Withdrawn |
Phase 2 |
|
66778-36-7 |
48041 |
Synonyms:
(+-)-2'-[2-(1-Methyl-2-piperidyl)ethyl]-p-anisanilide
(+-)-4-Methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide
(±)-2'-[2-(1-METHYL-2-PIPERIDYL)ETHYL]-P-ANISANILIDE
(±)-4-METHOXY-N-(2-(2-(1-METHYL-2-PIPERIDINYL)ETHYL)PHENYL)BENZAMIDE
4-Methoxy-2'-[2-(1-methyl-2-piperidyl)ethyl]benzanilide
4-Methoxy-N-{2-[2-(1-methyl-piperidin-2-yl)-ethyl]-phenyl}-benzamide
Bristol myers squibb brand OF encainide hydrochloride
Bristol-myers squibb brand OF encainide hydrochloride
|
Encainida
ENCAINIDE
Encainide hydrochloride
Encainide hydrochloride, (+-)-isomer
Encainide, (-)-isomer
Encainide, (+)-isomer
Encainidum
Enkaid
|
|
35 |
|
Tacrolimus |
Approved, Investigational |
Phase 2 |
|
104987-11-3 |
6473866 445643 |
Synonyms:
(-)-FK 506
Anhydrous tacrolimus
Anhydrous, tacrolimus
Cilag brand OF tacrolimus
FK5
FK506
FK-506
FK506|fujimycin|Prograf®|Protopic®
FR-900506
FUJIMYCIN
Fujisawa brand OF tacrolimus
Janssen brand OF tacrolimus
|
K506
LCP-Tacro
Prograf
Prograft
PROTOPIC
Tacarolimus
TACROLIMUS
Tacrolimus anhydrous
tacrolimus hydrate
TACROLIMUS MONOHYDRATE
Tacrolimus, anhydrous
|
|
36 |
|
Histamine |
Approved, Investigational |
Phase 2 |
|
51-45-6 |
774 |
Synonyms:
1H-Imidazole-4-ethanamine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
|
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Eramin
Ergamine
Ergotidine
Histamine
HSM
Imidazole-4-ethylamine
NSC-33792
Î’-imidazolyl-4-ethylamine
|
|
37 |
|
Tranilast |
Investigational |
Phase 2 |
|
53902-12-8 |
5282230 |
Synonyms:
MK 341
MK-341
N-(3,4-Dimethoxycinnamoyl)anthranilic acid
|
SB-252218
Tranilast
Tranilastum
|
|
38 |
|
Adrenergic Agents |
|
Phase 2 |
|
|
|
39 |
|
Anti-Arrhythmia Agents |
|
Phase 2 |
|
|
|
40 |
|
Sodium Channel Blockers |
|
Phase 2 |
|
|
|
41 |
|
Psychotropic Drugs |
|
Phase 2 |
|
|
|
42 |
|
Antidepressive Agents, Tricyclic |
|
Phase 2 |
|
|
|
43 |
|
Antidepressive Agents |
|
Phase 2 |
|
|
|
44 |
|
Calcineurin Inhibitors |
|
Phase 2 |
|
|
|
45 |
|
Immunosuppressive Agents |
|
Phase 2 |
|
|
|
46 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
47 |
|
Neurotransmitter Agents |
|
Phase 2 |
|
|
|
48 |
|
Anti-Allergic Agents |
|
Phase 2 |
|
|
|
49 |
|
Calcium, Dietary |
|
Phase 2 |
|
|
|
50 |
|
Platelet Aggregation Inhibitors |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 54)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Efficacy and Safety of Danggui-Sayuk-Ga-Osuyu-Saenggang-tang on Korean Patients With Cold Hypersensitivity in the Hands |
Completed |
NCT02645916 |
Phase 4 |
Danggui-Sayuk-Ga-Osuyu-Saenggang-tang;Placebo: corn starch |
2 |
Effect of Korean Red Ginseng on Women With Cold Hypersensitivity of Hands and Feet : a Randomized, Double-blind, Placebo-controlled Trial |
Completed |
NCT01664156 |
Phase 4 |
Korean red ginseng;Placebo |
3 |
Cathflo Activase (Alteplase) Pediatric Study (CAPS) |
Completed |
NCT00307580 |
Phase 4 |
Cathflo Activase (Alteplase) |
4 |
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study (The CAPS-PAH Study) |
Terminated |
NCT02253394 |
Phase 4 |
Ambrisentan plus Spironolactone;Ambrisentan plus Placebo |
5 |
An Open-label, Long-term Safety and Efficacy Study of ACZ885 (Anti-interleukin-1β Monoclonal Antibody) Administered for at Least 6 Months in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease |
Completed |
NCT00685373 |
Phase 3 |
Canakinumab (ACZ885) |
6 |
An Open-label, Efficacy and Safety Study of Canakinumab (Anti-interleukin-1β Monoclonal Antibody) Administered for 6 Months (24 Weeks) in Japanese Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease, Followed by an Extension Phase to Provide Canakinumab to Study Patients Until it is Approved and Marketed in Japan |
Completed |
NCT00991146 |
Phase 3 |
canakinumab |
7 |
An Open-label Extension Study to Assess Efficacy, Safety and Tolerability of Canakinumab and the Efficacy and Safety of Childhood Vaccinations in Patients With Cryopyrin Associated Periodic Syndromes (CAPS) |
Completed |
NCT01576367 |
Phase 3 |
|
8 |
A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS) |
Completed |
NCT01302860 |
Phase 3 |
ACZ885 |
9 |
An Open Label Study to Assess the Safety, Tolerability and Efficacy of Canakinumab (ACZ885) in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada |
Completed |
NCT01105507 |
Phase 3 |
canakinumab (company code: ACZ885D) |
10 |
IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal Designs |
Completed |
NCT00288704 |
Phase 3 |
rilonacept 160 mg;Placebo |
11 |
A Three-part,Multicenter Study,With a Randomized,Double-blind,Placebo Controlled,Withdrawal Design in Part II to Assess Efficacy,Safety,and Tolerability of ACZ885(Anti-interleukin-1beta Monoclonal Antibody)in Patients With Muckle-Wells Syndrome |
Completed |
NCT00465985 |
Phase 3 |
ACZ885;Placebo |
12 |
Efficacy and Safety of Ojeok-san on Korean Patients With Cold Hypersensitivity in the Hands and Feet - A Randomized, Double-blinded, Placebo Controlled, Multi-center Pilot Study |
Completed |
NCT03083522 |
Phase 3 |
Ojeok-San;Placebo |
13 |
Efficacy and Safety of Ucha-Shinki-Hwan on Korean Patients With Cold Hypersensitivity in the Hands and Feet-Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial |
Completed |
NCT03790033 |
Phase 2, Phase 3 |
Ucha-Shinki-Hwan;Placebo |
14 |
Efficacy and Safety of Sipjeondaebo-tang on Korean Patients With Cold Hypersensitivity in the Hands and Feet (SDT) |
Completed |
NCT03374345 |
Phase 2, Phase 3 |
Sipjeondaebo-tang Granule;Placebo |
15 |
Multi-center Pivotal Clinical Trial to Compare the Safety and Effectiveness of Procedural Sedation in GI Endoscopy: A Computer-Assisted Personalized Sedation (CAPS) Device Versus Current Standard of Care |
Completed |
NCT00452426 |
Phase 3 |
|
16 |
A Prospective, Randomized, Controlled, Double-Blind Study That Evaluates the Safety and Efficacy of Three Active REVIAN Caps Versus a Non-Active REVIAN Cap (Sham) in Participants With Pattern Hair Loss (Androgenic Alopecia) |
Completed |
NCT04019795 |
Phase 3 |
|
17 |
Heat Loss Prevention in Delivery Room: a Prospective, Randomised, Controlled Trial of Polyethylene Caps in Very Preterm Infants |
Completed |
NCT00930917 |
Phase 3 |
|
18 |
A Multi-Center, Open Label, 24-Month Treatment Study to Establish the Safety, Tolerability, Efficacy, Pharmacokinetics of Canakinumab (Anti-IL-1 Beta Antibody) in Patients With NOMID / CINCA Syndrome |
Terminated |
NCT00770601 |
Phase 3 |
Canakinumab |
19 |
A Phase 2a, Prospective, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS) |
Completed |
NCT05186051 |
Phase 2 |
ZYIL1 capsule |
20 |
A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany With Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome (CAPS), or Schnitzler Syndrome (SchS) |
Completed |
NCT01045772 |
Phase 2 |
rilonacept |
21 |
Pilot Trial of Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling (ELASTO-GEL CAPS)in Breast Cancer Patients |
Completed |
NCT00515762 |
Phase 2 |
|
22 |
PreCoCa - "Prehospital Cooling With Cool-Caps" |
Completed |
NCT00398671 |
Phase 2 |
|
23 |
Cardiac Arrhythmia Pilot Study (CAPS) |
Completed |
NCT00000504 |
Phase 2 |
encainide;moricizine;flecainide;imipramine |
24 |
Ph 2 Double-blind, Double-dummy, Multicenter, Prospective, Rand Study of PK of LCP-Tacroâ„¢ Tablets Once Daily, Compared to Prograf® Caps, Twice Daily, for Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients |
Completed |
NCT01666951 |
Phase 2 |
LCP-Tacro tablets;Prograf |
25 |
Efficacy and Safety of Tranilast in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS): A Single-Arm Prospective Cohort Study |
Recruiting |
NCT03923140 |
Phase 2 |
Tranilast |
26 |
An Open-label, Single Arm Phase II Study of DFV890 to Assess the Safety, Tolerability and Efficacy in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS) |
Recruiting |
NCT04868968 |
Phase 2 |
DFV890 |
27 |
An Open Label, Single Arm Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of HL2351 in Patients With Cryopyrin Associated Periodic Syndromes |
Terminated |
NCT02853084 |
Phase 2 |
HL2351 |
28 |
A Long-Term Outcome Study With the IL-1 Receptor Antagonist Anakinra/Kineret in Patients With Neonatal Onset Multisystem Inflammatory Disease (NOMID/CINCA Syndrome) A Therapeutic Approach to Study the Pathogenesis of This Disease |
Terminated |
NCT00069329 |
Phase 1, Phase 2 |
anakinra |
29 |
A Phase 2a, Open-Label, Single-Arm Study to Investigate the Safety and Efficacy of ATI-450 for the Maintenance of Remission in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS) Previously Managed With Anti-IL-1 Therapy |
Terminated |
NCT04524858 |
Phase 2 |
ATI-450 |
30 |
A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome (FCAS) / Muckle-Wells Syndrome (MWS) and Behcet's Disease (BD) |
Withdrawn |
NCT01211977 |
Phase 1, Phase 2 |
XOMA 052 |
31 |
A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of IZD334 in Healthy Adult Participants as Well as an Open-label Cohort to Confirm the Safety, Pharmacokinetics, and Pharmacodynamics in Adult Patients With Cryopyrin-Associated Periodic Syndromes |
Completed |
NCT04086602 |
Phase 1 |
IZD334;Placebos |
32 |
A Phase 1, Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Inzomelid in Healthy Adult Participants as Well as an Open Label Cohort to Confirm the Safety, Pharmacokinetics, and Pharmacodynamics of Inzomelid in Adult Patients With Cryopyrin-Associated Periodic Syndromes |
Completed |
NCT04015076 |
Phase 1 |
Inzomelid;Placebo |
33 |
The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria |
Completed |
NCT00214851 |
Phase 1 |
Kineret (anakinra) |
34 |
Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Oseltamivir From Oseltamivir 75 mg Caps (Pharmacare PLC, Palestine) and Tamiflu® 75 mg Caps (Hoffmann-La Roche, Switzerland) |
Completed |
NCT02507648 |
Phase 1 |
Oseltamivir;Tamiflu® |
35 |
Double-blind Randomised Placebo-controlled Study of Prolardii Gastro-resistant (GR) Caps in the Prevention and Treatment of Antibiotic-associated Diarrhoea. |
Unknown status |
NCT03256708 |
|
|
36 |
Cohort Study to Assess Electronic-caps Defined Adherence Patterns - Virological Outcome Relationship Amongst HIV-1 Infected Subjects Receiving Dolutegravir-Based Antiretroviral Therapy) |
Unknown status |
NCT02878642 |
|
|
37 |
Non-interventional PASS to Evaluate Safety of Kineret in Treatment of CAPS in Routine Clinical Care With Regard to Serious Infections, Malignancies, Injection Site Reactions, Allergic Reactions, Medication Errors Including Re-use of Syringe |
Completed |
NCT02326376 |
|
anakinra (Kineret) |
38 |
An Open-label, Long-term, Prospective, Observational Study to Monitor the Safety and Effectiveness of Ilaris in CAPS Patients |
Completed |
NCT01213641 |
|
|
39 |
International CAPS Registry: Operated Cases and Cases With Advanced Disease Among High-risk Individuals Participating in a Pancreatic Cancer Surveillance Program; a Case-control Study |
Completed |
NCT02703545 |
|
|
40 |
Care After Pregnancy Study (CAPS): Randomized Controlled Trial of Patient Engagement After Pregnancy |
Completed |
NCT04257552 |
|
|
41 |
Coaching Alternative Parenting Strategies (CAPS) Study: Targeting Neurobiological and Behavioral Mechanisms of Self-regulation in High-risk Families |
Completed |
NCT02684903 |
|
|
42 |
Understanding the Feasibility of Ripple Health Smart Pill Caps in Clinical Settings, and the Devices' Effects on Medical Interventions. |
Completed |
NCT05192928 |
|
|
43 |
Radioprotective Light-weight Caps in the Interventional Cardiology Setting: a Randomized Controlled Trial |
Completed |
NCT01620658 |
|
|
44 |
Study on the Reduction of Catheter-related Infections by Use of Self-disinfecting Venous and Arterial Access Caps |
Completed |
NCT04534348 |
|
|
45 |
Clinical and Multi-omics Cross-phenotyping of Patients With Autoimmune and Auto-inflammatory Diseases |
Recruiting |
NCT02466217 |
|
|
46 |
Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases) |
Recruiting |
NCT02974595 |
|
|
47 |
Pathogenesis and Genetic Basis of Physical Induced Urticarial Syndromes |
Recruiting |
NCT00887939 |
|
|
48 |
Clinical Characteristic and Quality of Life Assessment in Adulthood of Patients With Cryopyrin Associated Periodic Syndrome |
Recruiting |
NCT04856540 |
|
|
49 |
The Impact of Structured Caregiver Peer Support (CaPS) on ART Adherence and Viral Suppression Among Children Living With HIV in Nigeria |
Recruiting |
NCT04222270 |
|
|
50 |
Psychometric Evaluation of the Clinician Administered PTSD Scale for DSM-5 (CAPS-5) and the PTSD Symptom Scale Interview for DSM-5 (PSSI-5) in an Active Duty and Military Veteran Sample |
Recruiting |
NCT04180930 |
|
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
|